相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation
David B. Vaught et al.
CANCER RESEARCH (2012)
A functional comparison between the HER2high/HER3 and the HER2low/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
Sangmin Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis
Rebecca S. Cook et al.
CANCER RESEARCH (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival A Study of 4046 Patients
Connie G. Chiu et al.
ANNALS OF SURGERY (2010)
Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer Promising Clinical Target or Only a Marker?
Monika L. Burness et al.
CANCER JOURNAL (2010)
The HER3/ErbB3 receptor: A promising target in cancer drug therapy
C. Desbois-Mouthon
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE (2010)
Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
S. Gori et al.
ANNALS OF ONCOLOGY (2009)
Invasive ductal carcinoma of the breast with the triple-negative phenotype: prognostic implications of EGFR immunoreactivity
Giuseppe Viale et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Quantitative Multiplexed Analysis of ErbB Family Coexpression for Primary Breast Cancer Prognosis in a Large Retrospective Cohort
Jennifer M. Giltnane et al.
CANCER (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
The ERBB3 receptor in cancer and cancer gene therapy
G. Sithanandam et al.
CANCER GENE THERAPY (2008)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Seiji Yano et al.
CANCER RESEARCH (2008)
The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies
Anne W. Hamburger
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
Andrea Sassen et al.
BREAST CANCER RESEARCH (2008)
Targeting HER proteins in cancer therapy and the role of the non-target HER3
A. C. Hsieh et al.
BRITISH JOURNAL OF CANCER (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
Trastuzumab: triumphs and tribulations
R. Nahta et al.
ONCOGENE (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
HER2 therapy - Molecular mechanisms of trastuzumab resistance
Rita Nahta et al.
BREAST CANCER RESEARCH (2006)
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival
SM Wiseman et al.
CANCER (2005)
HER-2 testing in breast cancer using parallel tissue-based methods
H Yaziji et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer
CJ Witton et al.
JOURNAL OF PATHOLOGY (2003)
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival
Z Suo et al.
JOURNAL OF PATHOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
分享论文
